Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $8.4 million.

  • Myriad Genetics' Change in Accured Expenses rose 27.27% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year increase of 33.74%. This contributed to the annual value of -$41.0 million for FY2024, which is 250.74% down from last year.
  • Myriad Genetics' Change in Accured Expenses amounted to $8.4 million in Q3 2025, which was up 150.00% from -$16.8 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Change in Accured Expenses registered a high of $71.9 million during Q2 2023, and its lowest value of -$59.4 million during Q4 2023.
  • In the last 3 years, Myriad Genetics' Change in Accured Expenses had a median value of -$6.5 million in 2023 and averaged -$3.1 million.
  • As far as peak fluctuations go, Myriad Genetics' Change in Accured Expenses slumped by 7,000.00% in 2021, and later spiked by 4,340.00% in 2023.
  • Over the past 5 years, Myriad Genetics' Change in Accured Expenses (Quarterly) stood at -$14.2 million in 2021, then soared by 80.28% to -$2.8 million in 2022, then tumbled by 2,021.43% to -$59.4 million in 2023, then skyrocketed by 53.70% to -$27.5 million in 2024, then rose by 27.27% to $8.4 million in 2025.
  • Its Change in Accured Expenses was $8.4 million in Q3 2025, compared to -$16.8 million in Q2 2025 and -$12.4 million in Q1 2025.